Cure My Disease

Don't miss your cure!

 Log in / Sign up

Double defense: new mRNA vaccine targets two lung viruses in seniors

NCT ID NCT06686654

Vaccine Sponsor: Sanofi Pasteur, a Sanofi Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new mRNA vaccine designed to protect adults aged 60 and older from two viruses that can cause serious lung infections: human metapneumovirus (hMPV) and respiratory syncytial virus (RSV). About 1,530 participants will receive either the vaccine or a placebo to check safety and immune response. The trial also looks at how well a booster shot works a year after the first vaccination.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

1,530 people

The number who actually took part.

Started

Nov 2024

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 60 years or older on the day of inclusion * A female participant is eligible to participate if she is not pregnant or breastfeeding and is of non-childbearing potential. To be considered of non-childbearing potential, a female must be postmenopausal for at least 1 year or surgically sterile Exclusion Criteria: * Any screening laboratory parameter with laboratory abnormality \> Grade 1 deemed clinically significant by the investigator * Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months). Of note, persons living with stable human immunodeficiency virus (HIV) are not excluded * Known systemic hypersensitivity to any of the study intervention components (eg, polyethylene glycol, polysorbate); history of a life-threatening reaction to the study interventions used in the study or to a product containing any of the same substances; any allergic reaction (eg, anaphylaxis) after administration of an mRNA vaccine * History of RSV and/or hMPV-associated illness, diagnosed serologically or microbiologically in the last 12 months * Previous history of myocarditis, pericarditis, and/or myopericarditis * Screening electrocardiogram that is consistent with possible myocarditis, pericarditis, and/or myopericarditis or, in the opinion of the investigator, demonstrates clinically relevant abnormalities that may affect participant safety or study results * Laboratory-confirmed thrombocytopenia, contraindicating IM injection, based on investigator's judgment * Bleeding disorder or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM injection, based on investigator's judgment * Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion * Receipt of any vaccine other than mRNA vaccine in the 28 days preceding any study intervention administration or planned receipt of any vaccine other than mRNA vaccine in the 28 days following any study intervention administration * Receipt of any mRNA vaccine in the 60 days preceding any study intervention administration or planned receipt of any mRNA vaccine in the 60 days following any study intervention administration * Previous vaccination against RSV and/or hMPV (with a licensed or investigational vaccine either as a monovalent vaccine or any combination of the antigens) * Receipt of immune globulins, blood, or blood-derived products in the past 3 months Note: The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Human metapneumovirus immunization are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

respiratory syncytial virus infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Human metapneumovirus immunization Respiratory syncytial virus immunization

Contacts and locations

Locations

  • CenExel CNS-Garden Grove- Site Number : 8400017

    Garden Grove, California, 92845, United States

  • National Research Institute - Gardena- Site Number : 8400005

    Gardena, California, 90247, United States

  • National Research Institute - Huntington Park- Site Number : 8400014

    Huntington Park, California, 90255, United States

  • National Research Institute - Panorama City- Site Number : 8400012

    Los Angeles, California, 91402, United States

  • Peninsula Research Associates- Site Number : 8400002

    Rolling Hills Estates, California, 90274, United States

  • Providence Clinical Research - North Hollywood- Site Number : 8400018

    North Hollywood, California, 91606, United States

  • Suncoast Research Associates - Miami - Sunset Drive- Site Number : 8400001

    Miami, Florida, 33173, United States

  • Velocity Clinical Research - Austin- Site Number : 8400020

    Cedar Park, Texas, 78613, United States

  • Velocity Clinical Research - Denver- Site Number : 8400016

    Englewood, Colorado, 80110, United States

  • Velocity Clinical Research - Hallandale Beach- Site Number : 8400022

    Hallandale, Florida, 33009, United States

  • Velocity Clinical Research - Hampton- Site Number : 8400026

    Hampton, Virginia, 23666, United States

  • Velocity Clinical Research - Kansas City- Site Number : 8400015

    Overland Park, Kansas, 66210, United States

  • Velocity Clinical Research - Lincoln - Valley Road- Site Number : 8400023

    Lincoln, Nebraska, 68510, United States

  • Velocity Clinical Research - Medford- Site Number : 8400024

    Medford, Oregon, 97504, United States

  • Velocity Clinical Research - Meridian- Site Number : 8400003

    Meridian, Idaho, 83642, United States

  • Velocity Clinical Research - Omaha- Site Number : 8400006

    Omaha, Nebraska, 68134, United States

  • Velocity Clinical Research - Rockville- Site Number : 8400011

    Rockville, Maryland, 20854, United States

  • Velocity Clinical Research - Salt Lake City- Site Number : 8400010

    West Jordan, Utah, 84088, United States

  • Velocity Clinical Research - San Diego- Site Number : 8400008

    La Mesa, California, 91942, United States

  • Velocity Clinical Research - Seattle- Site Number : 8400019

    Seattle, Washington, 98105, United States

  • Velocity Clinical Research - Springdale- Site Number : 8400004

    Cincinnati, Ohio, 45246, United States

  • Velocity Clinical Research - Washington DC- Site Number : 8400007

    Washington D.C., District of Columbia, 20016, United States

  • Velocity Clinical Research Los Angeles- Site Number : 8400013

    Los Angeles, California, 90017, United States

  • Velocity Clinical Research, Phoenix- Site Number : 8400025

    Phoenix, Arizona, 85006, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.